The subject matter described herein relates to systems and methods for controlling fluid flow to a patient through a fluid pathway.
There are a number of patient clinical settings including in-hospital, outpatient, in-home care and emergency medical services (EMS) that require fluid administration to a patient. Standard clinical best practice is to label fluids intended to be delivered to patients to reduce the potential for errors. However, mistakes in compatibility of fluids with a particular patient, incorrect dose measurements, inappropriate sequence of medications, incorrect transfer of labeling information and other factors continue to be major obstacles to overcome in providing safe patient care.
The systems, apparatus, methods, and articles described herein provide mechanisms for preventing and/or mitigating patient fluid administration errors.
In one aspect, a system is provided that includes a fluid port, at least one sensor, a flow controller, and a flow control valve. The fluid port can include a fluid channel, a fluid inlet at a first end of the fluid channel configured to couple to an outlet of a manually administrable fluid source, and a fluid outlet at a second end of the fluid channel configured to deliver fluid from the manually administrable fluid source to a fluid pathway that provides fluid to a patient. The at least one sensor characterizes at least one attribute of the fluid from the manually administrable fluid source. The flow controller is in communication with the at least one sensor and generates at least one flow modification signal in response to the characterized at least one attribute matching at least one condition specified by at least one rule. The flow control valve is in communication with the flow controller and positioned along the fluid pathway at a location separate and distinct from the fluid port. The flow control valve changes a level of flow restriction of fluid from the manually administrable fluid source passing therethrough in response to receiving the at least one flow modification signal.
The at least one sensor can characterize at least one attribute of the fluid from the manually administrable fluid source (i) when the manually administrable fluid source is being coupled to the fluid inlet, (ii) when the manually administrable fluid source is coupled to the fluid inlet, and/or (iii) when fluid is passing through the fluid channel.
The at least one sensor can be integral or coupled to the fluid port. In other variations, the at least one sensor can be separate and distinct from the fluid port. In addition, multiple flow control valves at different points along the fluid pathway can be implemented in some variations. In addition, the flow control valve can be on the fluid pathway downstream from the fluid port and/or upstream from the fluid port.
Changing a level of flow restriction of fluid from the manually administrable fluid source passing through the flow control valve can include (i) stopping all fluid from passing through the flow control valve, and/or (ii) adjusting a current flow rate of fluid passing through the flow control valve to a higher or lower flow rate.
The flow controller can include or be in communication (e.g., via a computer network, via a wireless network, etc.) with a rules engine (which can be software and/or hardware implemented). Such a rules engine can use a plurality of rules to determine whether the at least one attribute matches the at least one condition specified by the at least one rule. The flow controller can, in some variations, poll at least one remote data source to obtain at least a portion of the rules. The rules engine, when applying the rules, can use (i) the at least one attribute, (ii) manually-entered user input, and (iii) flow control input data selected from a group consisting of: fluid information, patient-specific information, medical order information, clinical guideline information, environmental factors, flow control valve status, and historical information in order to determine whether there is a match for the at least one condition.
The fluid port can include a wireless transceiver for transmitting and receiving data to and from the flow controller, and the flow controller further comprises a wireless transceiver for transmitting and receiving data to and from the fluid port. In addition, the flow controller can transmit data to an external device other than the fluid port characterizing a state of the flow control valve.
The outlet of the manually administrable fluid source can include fluid source information encoded thereon. In such cases, the at least one sensor can include an identification sensor that detects the manually administrable fluid source information when the manually administrable fluid source is being coupled or is coupled to the fluid port inlet. The fluid source information can be a code or identifier used to reference a secondary data set that is characteristic of the fluid contained within the manually administrable fluid source. This secondary data set can be stored in memory (which can optionally form part of the fluid port). The secondary data set can be stored in a remote data source coupled to the flow controller via a communications network. The remote data source can form part of a medical device and/or a medical information system. The at least one flow modification signal can be generated using a rules engine that processes the detected fluid source information.
The at least one sensor can be a fluid composition sensor that characterizes a composition of fluid. The fluid composition sensor can be located along the fluid channel between the fluid inlet and fluid outlet. The at least one attribute can be indicative of at least one constituent present in fluid flowing through the channel. The at least one flow modification signal can be generated using a rules engine that processes the result of the sensed fluid composition information.
Contents from the manually administrable fluid source do not reach the patient for at least a time T1 after the manually administrable fluid source begins fluid delivery into the fluid inlet. To accommodate this arrangement, the flow controller and the flow control valve can be configured to restrict flow in the fluid pathway within a time T2<T1 after the manually administrable fluid source begins fluid delivery into to the fluid inlet.
Various elements forming part of the system may have wireless transmitters, receivers, and/or transceivers. A wireless transmitter can be provided to transmit data from the at least one sensor to the flow controller. A wireless transceiver can be coupled to the flow controller to receive and transmit data relating to operation of the flow control valve. A wireless receiver can be coupled to the flow control valve to receive a flow modification signal from the flow controller. A wireless transmitter can be coupled to the flow control valve to send information to the flow controller indicative of a change in the level of fluid flow restriction being applied to fluid passing through the flow control valve in response to receiving the at least one flow modification signal from the flow controller.
The at least one sensor can be any of a variety of sensors including identification sensors, flow sensors, and composition sensors.
The fluid can be a medication and the at least one attribute can characterize one or more: medication type, medication concentration, medication volume, medication expiration date, a dosage form of the medication, dose instructions for the medication, administration instructions for a specific patient, medication formulation, medication manufacturer information, a re-packager of the medication, a distributor of the medication, medication package form, medication package size, medication package serial number, medication lot number, blood type, an RxNorm identification code, an NDC code (National Drug Code), a segment of an NDC code identifying a corresponding medication product, a segment of an NDC code identifying a corresponding medication package, a unique identifier code, a human readable alphanumeric string, and a machine readable code.
The at least one flow modification signal can be automatically initiated and executed by the flow controller without user intervention. The at least one flow modification signal can be automatically initiated and executed by the flow controller as a result of coupling the outlet of the manually administrable fluid source to the fluid inlet and/or as a result of sensing the start of fluid flow into the fluid inlet.
An interface (e.g., display, GUI, etc.) can be included that provides audio and/or visual feedback to a user characterizing the at least one attribute and/or fluid contained within the manually administrable fluid source. The interface can provide an indication to the user of a state of the flow control valve. The interface can allow a user to input information to be used by the flow controller, in combination with information from the at least one sensor, to determine whether to generate the at least one flow modification signal. In cases in which the fluid is medication, the interface can display administration information and/or instructions associated with the medication. Such administration information and/or instructions can be stored within memory forming part of the system. A communications module can be provided to transmit and/or receive the administration information and/or instruction to/or from a remote data source. The interface can be adjacent to the fluid port or remote from the fluid port. The interface can display information about various aspects of fluid flow such as flow rate, composition, and the like.
A manual override element can be provided, which when activated by a user, causes the flow controller to cause the flow control valve to stop fluid flow in a first state or to allow fluid to flow in a second state.
A communications module can be provided to transmit and/or receive flow control input data, rules engine output data and/or data characterizing the fluid source to or from a remote data processing system.
There can be a plurality of fluid inlets such that each is configured to couple to an outlet of one of a plurality of manually administrable fluid sources. There can be a corresponding number of flow control valves that are coupled to the flow controller to selectively prevent fluid flowing from at least one of the plurality of fluid inlets.
The flow controller can receive data specifically relating to the patient that can be used, in combination with information from the at least one sensor and/or information manually-entered by the user, to determine whether to generate the at least one flow modification signal. Data relating to the patient can include at least one medication order. The at least one medication order can be used to confirm whether the fluid in the manually administrable fluid source matches the at least one condition specified by the at least one rule specified by the at least one medication order. The data characterizing the patient can include a patient identifier and the flow controller can poll at least one remote data store using the patient identifier to obtain reference information to determine whether to generate the at least one flow modification signal.
The at least one sensor can be a fluid flow sensor. Fluid flow information sensed by the fluid flow sensor can cause the flow controller to generate a first flow modification signal to cause the flow control valve to transition to a first state when a first pre-determined volume has been delivered as measured by the fluid flow sensor, and after a pre-determined span of time, cause the flow controller to generate a second flow modification signal to cause the flow control valve to transition to a second state different than the first state.
The at least one sensor can be an identification sensor that generates the at least one attribute using one or more technologies selected from a group including: optical, magnetic, mechanical, conductive, switchable, infrared, switchable RFID, and proximity sensors.
The at least one sensor can be a composition sensor that generates the at least one attribute using one or more technologies selected from a group including: photometric analysis, electrometric analysis, chromatography, mass spectroscopy, physical property measurements, or parametric analysis based on a combination of technologies.
The at least one sensor can be a fluid flow sensor that generates the at least one attribute using one or more technologies selected from a group including: a paddle wheel flow meter, a turbine flow meter, a thermal flow meter, an ultrasonic flow meter, a pressure sensor, a differential pressure sensor, an optical sensor, an ultrasonic sensor, a coriolis flow meter, a displacement sensor.
Some or all of the system can be enclosed by a housing. The housing can take different shapes and sizes. In some implementations, the housing envelopes at least a portion of each of the fluid inlet, the fluid outlet, the flow controller, and the at least one sensor. The housing can have a shape and size allowing a user to hold the housing in a first hand while coupling the manually administrable fluid source in a second hand. A self-contained power source can be provided within the housing to power the at least one sensor and/or other components. The fluid pathway can be an intravenous (IV) fluid line and the housing can be suspended on the IV fluid line.
The housing can include a reusable sub-housing and a disposable sub-housing. The reusable sub-housing can be operatively coupled to the disposable sub-housing and the reusable sub-housing is intended for use by a plurality of patients and the disposable sub-housing is intended for use by a single patient. In some variations, the at least the fluid inlet, fluid outlet, and flow channel can be enclosed by the disposable sub-housing. The disposable sub-housing can be included in a sterile pouch enveloping the disposable sub-housing. Memory can be placed within the disposable sub-housing for storing data used by the flow controller to determine whether to generate the at least one flow modification signal.
The manually administrable fluid source can be of any variety of medication containers/delivery mechanisms. Examples include, but are not limited to, syringes, IV bags, disposable medication cartridges, disposable medication pouches, and IV tubing.
In an interrelated aspect, a system includes a fluid port, at least one sensor, a controller, and a transmitter. The fluid port includes a fluid channel, a fluid inlet at a first end of the fluid channel configured to couple to an outlet of a manually administrable fluid source, a fluid outlet at a second end of the fluid channel configured to deliver fluid from the manually administrable fluid source to a fluid pathway that provides fluid to a patient. The at least one sensor characterizes at least one attribute of the fluid from the manually administrable fluid source. The controller is in communication with the at least one sensor and it generates at least one operation modification signal in response to the characterized at least one attribute matching at least one condition specified by at least one rule. The transmitter wirelessly transmitting the operation modification signal to at least one device such that the operation modification signal, when received by the at least one device, causes the at least one device to modify at least one operating parameter. With this variation, different types of devices can be used other than a flow controller (although the operation modification signal can also act to cause a flow controller to modify some parameter relating to fluid flow). For example, a medical device interacting with the fluid pathway can cause the fluid flow within the fluid pathway to be adjusted and/or other non-fluid flow operating parameters of a medical device can be modified.
In another variation, different types of external devices (e.g. infusion pumps, syringe pumps, etc.) can receive operation modification signals from the flow controller and take appropriate actions. For example, a medical device interacting with the fluid pathway can, in response to an operation modification signal, cause the fluid flow within the fluid pathway to be stopped. Alternatively, other non-fluid flow operating parameters of a medical device, such as the posting of an alert or the logging of a flow rate, can be modified (i.e. acted upon) based on receipt of an operation modification signal.
In a further interrelated aspect, data is received that is generated by at least one sensor of a fluid port characterizing at least one attribute of fluid within a manually administrable fluid source. The fluid port includes a fluid channel, a fluid inlet at a first end of the fluid channel configured to couple to an outlet of the manually administrable fluid source, and a fluid outlet at a second end of the fluid channel configured to deliver fluid from the manually administrable fluid source to a fluid pathway that provides fluid to a patient, and the at least one sensor. Thereafter, it can be determined that the at least one attribute in the received data matches at least one condition specified by at least one rule. In response, at least one flow modification signal is generated. The at least one flow modification signal, when received by a flow control valve, causes the flow control valve to change a level of fluid flow restriction being applied to fluid passing through the flow control valve.
In another aspect, an apparatus includes a fluid inlet, a fluid outlet, a flow control valve, an identification sensor, and a flow controller. The fluid inlet is configured to couple to an outlet of a manually administrable fluid source having fluid source information encoded thereon. The fluid outlet is configured to deliver fluid from the manually administrable fluid source to a fluid line (pathway) leading to a patient. The flow control valve is disposed between the fluid inlet and the fluid outlet that prevents fluid flow in a first state and permits fluid flow in a second state. The identification sensor is positioned to detect the fluid source information when the manually administrable fluid source is being coupled or is coupled to the fluid inlet. The flow controller selectively causes the flow control valve to transition between the first state and the second state based on the fluid source information detected by the identification sensor.
The flow controller can use a plurality of rules to determine whether to transition the current state of the flow control valve to the other state. Some or all of the rules can be obtained from a remote data source polled by the flow controller. A rules engine (i.e., software and/or hardware for applying the rules, etc.) can take into account the fluid source information, flow control input data, and one or more attributes of the patient and their history, clinical circumstances, environmental factors, clinical best practices and the like. The rules engine can be configurable and programmable according to one or more of user-inputted specifications (via for example, an interface on the apparatus or via a remote computing system/interface, etc.), patient specific data, and/or medication specific data.
A fluid composition sensor can be additionally incorporated to characterize a composition of the fluid when the manually administrable fluid source is coupled to the fluid inlet. In some cases, the fluid composition sensor can be used in place of the identification sensor while in other implementations it is used in combination with the identification sensor. In either arrangement, the flow controller can further selectively cause the flow control valve to transition between the first state and the second state based on the fluid composition detected by the fluid composition sensor.
The flow controller can transmit data characterizing the fluid source information detected by the identification sensor to a remote rules engine that sends a signal indicating whether to change a current state of the flow control valve. The fluid source information can be indicative of a characteristic of the fluid (e.g., medication, etc.) contained therein and can include one or more of an RxNorm identification code, NDC code (National Drug Code), a segment of the NDC code identifying the drug product, a segment of the NDC code identifying the drug package, a unique identifier code, a human readable alphanumeric string, a machine readable code, a name of the medication, a manufacturer of the medication, a re-packager of the medication, a distributor of the medication, a strength of the medication, a dosage form of the medication, dose instructions for the medication, administration instructions for a specific patient, medication formulation, medication package form, medication package size, medication contained volume, medication package serial number, medication lot number, and medication expiration date, fluid type, and blood type. The fluid source information can include a code or identifier used to reference a secondary data set that is characteristic of the fluid contained therein (i.e., a reference to a lookup table, a database object, a URL, etc.). The apparatus can include memory that stores the secondary data set locally and/or a remote data store can be coupled to the flow controller that stores the secondary data set. The remote data store can form part of a medical device or medical information system.
The transition between states can be automatically initiated and executed by the flow controller without user intervention. The transition between states can be automatically initiated and executed by the flow controller as a result of coupling the fluid source outlet to the fluid inlet.
An interface can be included to provide audio and/or visual feedback to a user characterizing one or more of the fluid source information, volume of fluid administration, rules engine information, and/or rules engine output. The interface can provide an indication to the user when the flow control valve is in the first state, an indication to the user of one or more rules used by a rules engine causing a flow control valve state transition, and/or an indication to the user without a flow control valve state transition. The interface can be adjacent to the fluid inlet and/or it can be remote from the fluid inlet (e.g., a display monitor wirelessly coupled to the flow controller, etc).
The interface can display medication administration information associated with the fluid. Such medication administration information can be stored on local memory. A communications module can be included to transmit and/or receive the medication administration information to or from a remote data source. The interface can be adjacent to or remote from the fluid inlet.
A manual override element, which when activated by a user, can cause the flow controller to cause the flow control valve to transition from the first state to the second state.
A communications module can be included to transmit and/or receive data to or from a remote data source characterizing one or more of the flow control input data, fluid source, the rules or a portion of the rules, and/or the patient.
In some implementations, there can be a plurality of fluid inlets that are each configured to couple to an outlet of one of a plurality of manually administrable fluid sources each having fluid source information thereon. In these arrangements, there can be a plurality of flow control valves that are each coupled to the flow controller to selectively prevent fluid flow in at least one of the plurality of fluid inlets.
The flow control valve can be maintained in the first state until it is determined, by using the fluid source information, to transition the flow control valve to the second state. The flow control valve can be maintained in the second state until it is determined, by using the fluid source information, to transition the flow control valve to the first state. The flow controller can receive data characterizing the patient that is used, in combination with the fluid flow source information, to determine whether to transition the current state of the flow control valve. The data characterizing the patient can include, for example, a medication order that is used to confirm whether the fluid in the fluid source matches one or more parameters specified by the at least one medication order. The data characterizing the patient can include a patient identifier that the flow controller uses to poll at least one remote data store using the patient identifier to obtain reference information for the flow controller to determine whether to transition the current state of the flow control valve.
A fluid flow sensor can be utilized that measures how much fluid has been delivered from the fluid source into the fluid inlet. The flow controller can cause the flow control valve to transition from the second state to the first state when a pre-determined volume has been delivered as measured by the fluid flow sensor. An interface can provide audio and/or visual feedback indicating how much fluid has been delivered as measured by the fluid flow sensor. The flow controller can cause the flow control valve to transition from the second state to the first state when a first pre-determined volume has been delivered as measured by the fluid flow sensor, and after a pre-determined span of time, can cause the flow control valve to transition from the first state to the second state. The rules can utilize flow control input data information such as fluid information, patient-specific information, medical order information, clinical guideline information, contraindications, environmental factor information including time, flow control valve status, and historical information.
The identification sensor can detect the fluid source information using one or more technologies selected from a group consisting of: optical, magnetic, mechanical, conductive, switchable, infrared, switchable RFID and proximity sensors. In some cases, the identification sensor includes an optical element which detects an identifier encoded on a tip/outlet of the manually injectable medication container.
A housing can envelope at least a portion of each of the fluid inlet, the fluid outlet, the flow control valve, the identification sensor, and the flow controller. Such a housing can have a compact form/shape and size that allows a user to hold the housing in a first hand while activating the manually injectable medication container in a second hand. The housing can also include a self-contained power source within the housing powering the flow control valve, the identification sensor, and the flow controller and the fluid line can be an intravenous (IV) fluid line. The compact housing can, for example, be suspended from the IV fluid line.
The housing can be subdivided into reusable sub-housing and a disposable sub-housing. The reusable sub-housing can be operatively coupled to the disposable sub-housing with the reusable sub-housing being intended for use by a plurality of patients and the disposable sub-housing being intended for use by a single patient. The disposable sub-housing can contain at least the fluid inlet, fluid outlet, flow channel, and flow control valve. The disposable sub-housing can be part of a kit including a sterile pouch enveloping the disposable sub-housing. The disposable sub-housing can include memory for storing data that can include flow stop configuration information, flow sensor calibration information and/or a serial number or a unique identification number.
In an interrelated aspect, fluid source information of a manually administrable fluid source is detected by an identification sensor of a fluid delivery device, Thereafter, it is determined, using the detected fluid source information, whether to transition the current state of the flow control valve to the other state. A flow controller of the fluid delivery device then causes a flow control valve to transition to the other state (e.g., open or closed) if it is determined that the flow control valve should transition to the other state. Otherwise, the current state of the flow control valve is maintained if it is not determined that the flow control valve should transition to the other state.
In another variation a self-contained fluid port includes a fluid inlet for receiving manually administered medication, a fluid outlet for delivering the manually administered medication to a tubing segment leading to a patient, one or more sensors that sense one or more aspects of the injection of the medication, and electronics that wirelessly communicate the sensor information to external electronics. The one or more sensors may include one or more of a fluid source identification reader, a composition sensor, and a fluid flow sensor. The self-contained fluid port may be one integrally housed unit or it can include an electronics portion and a fluid portion. The electronics portion includes the electronics and may include a sensor such as a reader. The fluid portion may also include a fluid flow sensor.
In another variation, a fluid flow arrestor (flow control valve) can be physically separated from the self-contained fluid injection port and/or the fluid identification sensor and/or the fluid composition sensor. The fluid flow arrestor can be located upstream or downstream of the fluid injection port. The fluid flow arrestor can be within an external device like an infusion pump. A flow controller and/or a rules engine can be included to determine the appropriate state of the fluid flow arrestor (open or closed). The flow control valve can be responsive to a command from the flow controller and/or rules engine based on information provided by the fluid identification sensor and/or the fluid composition sensor. The flow control valve can be wirelessly connected or wired to the flow controller. The flow control valve can control the flow rate in a binary manor (open or closed) or it can restrict flow and limit the flow rate to a specific level. The flow controller and/or the rules engine can be external to the system and/or be distributed across several system elements. If distributed, the logic could cascade across systems (e.g.: if an outside rule is met AND an inside rule is met, THEN a trigger flow control command can be activated). The flow control valve can be powered by a self contained power source or connected to an external power source. The flow control valve can be a one-time activated device or can be resettable enabling repeat activation. The flow controller command signal can be published as an open-source such that any appropriate command could activate the flow control valve.
In another variation, the flow control valve can be part of a system to protect a patient from an inappropriate fluid administration. The system can include fluid flow paths with known volumes and flow rates. When a known volume of fluid is injected into a flowing fluid pathway the time for the injected fluid to reach the patient can be calculated. The flow control valve can be activated before the inappropriate fluid can reach the patient. A safety confirmation of fluid stop can be provided to the patient caregivers. Additionally, the fluid volume downstream from the injection port can be measured by fluid withdrawal into a syringe (pulling on an empty syringe connected to the injection port and withdrawing fluid into the syringe) with the upstream fluid pathway occluded (pinched off). The withdrawn downstream fluid volume can be measured manually by inspection of the syringe graduations or measured automatically by a fluid volume measurement sensor within the injection port apparatus. The measured downstream volume can be communicated to and stored in the rules engine. The downstream volume can then be used as an input to the flow controller.
In yet another variation, the fluid flow arrestor can include and/or be distributed between a disposable subsection and a reusable subsection. The interface between these subsections can be electrical, magnetic, mechanical, hydraulic, optical, capacitive. The disposable subsection can include the flow control valve only and the reusable subsection can include all the other components. Alternatively, the disposable subsection can include all the components including the flow control valve, power supply, wireless or wired communications and fluid path. In one variation, the disposable subsection includes portions of the fluid flow arrestor that are contacted with fluid and the reusable subsection includes portions of the fluid flow arrestor that do not contact fluid in order to minimize an expense of replacing the reusable subsection.
Computer program products are also described that comprise non-transitory computer readable media storing instructions, which when executed by at least one data processor of one or more computing systems, causes the at least one data processor to perform operations herein. Similarly, computer systems are also described that may include one or more data processors and a memory coupled to the one or more data processors. The memory may temporarily or permanently store instructions that cause at least one processor to perform one or more of the operations described herein. In addition, methods can be implemented by one or more data processors either within a single computing system or distributed among two or more computing systems. For example, the rules engine can be software-based or a combination of software-hardware based.
The accompanying drawings, which are incorporated in and constitute a part of this specification, show certain aspects of the subject matter disclosed herein and, together with the description, help explain some of the principles associated with the disclosed embodiments. In the drawings:
Like reference symbols in the various drawings indicate like or similar elements.
Described herein are systems and methods for controlling fluid delivery to a patient through a fluid delivery pathway. The systems and methods described herein incorporate rules-based clinical decision support logic to drive a flow control valve along a fluid flow pathway leading to patient based on a determination of whether or not a fluid connected to an input port is appropriate for delivery to a specific patient (consistent with medical orders, accepted delivery protocols, patient-specific characteristics, etc.). In an alternative configuration, decision logic used to control the flow valve along the fluid pathway can be based on whether or not a specific volume of fluid has been delivered through the input port to the patient, rather than, or in addition to, a determination that the fluid is appropriate for patient administration.
Independent of the rules and flow-stop criteria used to actuate the flow control valve, the flow control valve can be physically located anywhere along the fluid pathway, including but not limited to within the fluid port itself, such that closure of the flow control valve will prevent fluid entering the fluid port from reaching the patient. Moreover, the flow control valve can be an integral part of the systems described herein, or it can be associated with an external device and/or system (e.g. infusion pump, wireless, IV tubing clamp, etc.) that actuates the valve in response to a trigger signal received from the systems described herein.
It should be appreciated that use of the term “fluid” herein is not limited to any specific fluid and can include any type of therapeutic fluid. Fluids as used herein can include, but are not limited to medications, blood-based products, nutritional solutions, electrolytes, buffer solutions, lactated Ringer's solutions, sodium bicarbonate, crystalloids, colloids, saline solutions. Blood-based products can include, but are not limited to, any component of the blood for use in blood transfusions, whole blood, fresh frozen plasma, cryoprecipitate, blood substitutes, artificial blood, oxygen-carrying substitutes. Medications can include any therapeutic fluid that can be administered intravenously or via another appropriate parenteral route of administration such as intra-arterial, intraosseous, intracerebral, intracardiac, subcutaneous, or intraperitoneal.
It is standard practice to query patients and place in the patient file medical record information such as blood type, known drug allergies, drugs patient is currently taking, dietary restrictions, etc. This data provides a caregiver with information regarding potential adverse reactions a particular patient may experience upon administration of such fluids. In an in-hospital setting this patient-specific information typically is entered into an Admission, Discharge and Transfer (ADT) system or other clinical documentation system when the patient is first admitted to the hospital and used throughout their length of stay to help ensure safe care. Clinical guidelines and best practices also support a host of non-patient-specific medical information that can be routinely taken into consideration by prescribers of IV medications/fluids such that administering clinicians can avoid inducing patient adverse events. This information can include, but is not limited to drug-drug interactions, blood type matching, appropriate drug dosing limits, impact of current vital signs on treatments, metabolic factors and/or lab results.
Fluids can be delivered according to a medical order defined by a prescribing physician. Delivery orders can specify information such as type of fluid, medication dose, frequency of dose, administration route, etc. In an in-hospital setting these orders can originate from and/or be accessible through a Computerized Physician Order Entry (CPOE) system, Pharmacy Information System (PIS), Blood Bank Information System (BBIS), or Operating Room Information System (ORIS). Safe delivery of medications or other fluids to patients can require clinicians to execute according to the prescribed medical orders, while simultaneously taking into consideration patient-specific health characteristics (e.g. blood type) and history (e.g. medications previously administered, allergies), drug-specific clinical guidelines, and a host of environmental circumstances such as current vital signs, time, etc.
Turning now to
The microprocessor 125 can communicate with one or more external systems 135. Communication between the system 100 described herein and the one or more external systems 135 can include wired or wireless communication methods. The nature of the one or more external systems 135 can be in the form of tangible medical devices and/or systems such as IV infusion pumps, or software applications, including but not limited to, healthcare information systems such as PIS, BBIS, ORIS, or ADT systems. The system 100 can include a fluid source reader 145 coupled to the inlet 105 and configured to detect one or more information sources carried by the fluid source connected to the inlet 105. Information detected by the fluid source reader 145 can be indicative of a characteristic of the fluid contained within the associated fluid source container, such as type, volume, concentration, expiration, manufacturer's information regarding contents, etc. The information can be detected by the fluid source reader 145 according to a variety of methods, including but not limited to, optical, magnetic, mechanical, conductive, switchable, proximity sensors, IrDA, RFID, etc. Communication systems between inlets, fluid source readers and fluid source identification systems are described in detail in U.S. Patent Publication Nos. 2011/0112473, filed Nov. 6, 2009; 2011/0111794, filed Apr. 22, 2010; and 2011/0112474, filed Nov. 2, 2010, which are each incorporated by reference herein in their entirety.
The communication between the microprocessor 125 and the one or more external systems 135 can be bi-directional such that the microprocessor 125 can both receive and transmit flow control input data 140. Flow control input data 140 can include, but are not limited to, 1) information about the fluid source such as type of fluid, volume of fluid, concentration of fluid, etc.; 2) constant patient-specific information such as patient identification number, drug allergies, blood type, etc.; 3) variable patient-specific information such as patient vital signs, lab results, current disease states and/or clinical diagnoses, drugs previously administered, etc.; 4) medical orders such as drug, dose, route of administration, treatment schedule, etc.; 5) clinical guidelines such as known drug-drug interactions, recommended treatment protocols, dosing limits, etc.; 6) environmental factors such as the care area where treatment is being delivered, time of day, date, temperature, etc.; 7) valve status such as currently open (second state), currently closed (first state) or clinician initiation of a manual override; 8) historic patient information such as disease state, clinical diagnosis, dosing history, etc.; and 9) any other relevant information applicable to determining whether or a not a particular fluid administration is safe and appropriate for a patient. Communication between the system 100 and the one or more external systems 135 is discussed in more detail below.
The systems described herein are generally small and light-weight systems that can reduce the risk of serious medical errors and deaths by controlling flow through a fluid delivery pathway. It should be appreciated that the systems described herein can be applied to any care environment where fluids are delivered to patients, including hospitals, clinics, outpatient surgery centers, doctor's offices, home health settings, EMS, ambulances, etc.
The system 100 described herein can be enclosed by a small plastic housing such that fluid inlet 105 and outlet 110 are available for external connections. The housing can enclose the fluid flow path 120, one or more flow control valves 115, and a power source 155. The housing can additionally enclose one or more of a microprocessor 125, a memory 150, a transmitter/receiver 157, a rules engine 130, a fluid source reader 145, and a fluid flow sensor 149 and/or composition sensor 148 (described later). The housing can be a low-cost, single-patient use, sterile, disposable assembly. Alternatively, the housing can include most or all of the system components and be reusable and rechargeable. System 100 can include a user interface 160, located adjacent to the fluid inlet or remote from the fluid inlet, to provide information to/from a user regarding a fluid and/or medication, audio/visual feedback, status of the flow stop valve 115 and other care related details. Any one or more of the components of the system 100 can be included or excluded from the housing in any number of alternative implementations.
In some implementations, system 100 can be subdivided and have components distributed such that a portion resides within a disposable sub-housing and the remainder resides outside the disposable sub-housing. The disposable sub-housing 104 (see
As mentioned above, the system 100 can include a flow control valve 115 positioned within the fluid flow pathway 120 between the inlet 105 and the outlet 110. The flow control valve 115 can be a programmable valve that can toggle between two states in response to flow state commands 122 from the configurable rules engine 130. Flow control valve 115 can be limited to two operating modes, the first being an all-on “OPEN” state and the second being an all-off “CLOSED” state. Alternatively, flow control valve 115 can have multiple operating modes, including but not limited to, variable and intermittent flow control modes. Specific types of valves used can include, but are not limited to, gate valves, globe valves, T valves, butterfly valves, ball valves, check valves, plug valves, pinch valves, diaphragm valves, and the like.
A flow control valve 115 can be positioned within a single fluid flow pathway 120 between an input fluid connector 205a and an output fluid connector 290 (see
Similarly, the fluid source reader 145 (and/or composition sensor 148) can be positioned on various segments of the fluid flow pathway 120 depending on the configuration of the components in the set. In some implementations, the fluid source reader 145 can be positioned in an upstream location along the same flow path as the flow control valve 115 (
The microprocessor 125 can include a flow control valve software application in combination with rules engine 130 that evaluates combinations of flow control input data 140 against configurable logic for determining the proper state of the flow control valve 115 at any given time prior to or during a treatment regimen or fluid delivery protocol (see the diagram 300 of
The system 100 can be configured to operate in different operative modes. In some implementations, the system 100 can operate in a normally CLOSED mode where the baseline state of the flow control valve 115 is closed (first state) and the fluid flow pathway 120 is opened during a fluid delivery and then closed again upon completion of the delivery (see
As shown in the process flow diagram 400 of
If the system 100 does not fail one or more of the safety checks, the flow control valve 115, if closed, can be changed from a closed state to an open state (432). In some implementations, the system 100 can measure fluid volume in real-time during delivery of the fluid (434) and calculate the actual dose delivered and compare it to the ordered dose (436). The ordered “dose” can include a specific fluid volume (e.g. 1 liter of blood) or a quantity calculated by multiplying fluid volume by a fluid source concentration (e.g. 2 mL of 1 mg/mL concentration of morphine fluid source). Once the ordered dose is reached, the system 100 detects the fluid source is detached from the system 100, or fluid flow has stopped for a period long enough that the fluid flow controller can consider the dose administration to be complete, a flow state command 122 can be sent to close flow control valve 115 (440) in preparation for the next fluid administration. The administration conditions and results can be communicated to the system memory 150 and/or an external system 135 for recording (438).
In some implementations, the rules engine 130 logic can be defined such that triggering an alert or warning message to alert the clinician is an independent event from sending a flow state command 122 to flow control valve 115. Rules logic can generate tiered messages and/or flow state commands 122 using multiple trigger thresholds based on the severity of a potential safety risk. For example, if the physician-ordered dose for a fluid is 100 mL, the rules engine 130 can send a warning message to the clinician without closing the flow control valve 115 when the dose administered reaches 105 mL of fluid. However, if dose administration continues and the cumulative dose volume reaches 110 mL of fluid, the rules engine can send an alert message to the clinician while simultaneously sending a flow state command 122 to close flow control valve 115. The rules engine can poll remote data stores to obtain rules and/or flow control input data. This polling process may involve directly or indirectly utilizing subelements of flow control input data as reference parameters for accessing relevant external data. Such flow control input data can include, but not limited to, patient identifier information.
Referring now to the process flow diagram 500 of
If no safety checks are triggered, fluid volume can be measured in real-time during administration (532). Once it is determined that the ordered dose has been achieved, the fluid source is detached, or fluid flow has stopped for a period long enough that the fluid flow controller can consider the dose administration to be complete (534), then results can be transmitted to external system 135 (536).
As described above, the rules engine can also trigger messages independent of flow state command 122 which can include transmitting data to record the condition in memory 150 of system 100 and/or to one or more external systems 135. Such triggers can also drive inputs and outputs on user interface 160. For example, outputs to the user through user interface 160 can include audio feedback, changes to status indicators, fluid source information, fluid composition information, volume of fluid administered, information associated with the fluid (e.g. medication) administration, rules engine information and/or output, error messages, feedback on the state of the flow control valve, or other similar parameters. Similarly, inputs from the user can include, but are not limited to, confirming an action, confirming recognition of an alert, entry of a manual override request for the flow control valve, or a reset of the valve.
While the set and sequence of safety checks utilized in
In certain variations, certain elements of system 100 can be referred to as a housed and self contained fluid port 100. The elements of fluid port 100 minimally include fluid inlet 105, fluid flow pathway 120, at least one sensor (fluid identification sensor 145, and/or composition sensor 148, and/or fluid flow sensor 149), and wireless transmission electronics 157 that interface and/or communicate with the sensor 145 and/or 148 and/or 149 and communicate with systems that are external to the fluid port 100 in order to enable the actuation of a flow control valve 115. Fluid flow control valve 115 can be external to fluid port 100 as illustrated in
It should be appreciated that the use of multiple sensor types, used separately or in parallel, are fully applicable to the various fluid delivery set configurations described in
In some variations, flow control valve 115 can control the flow rate in a binary manner (open or closed) or in other variations it can partially restrict flow and thus limit the flow rate to a specific flow rate level. The flow control valve 115 can be powered by a self-contained power source or connected to an external power source. The flow control valve 115 can be a one-time activated device or can be resettable enabling repeat activation. The flow controller command signal 280 can be published as an open-source such that any appropriate system or device could send command 280 and activate flow control valve 115.
An example of the time calculations follows:
Therefore, calculating the time tx=t1+t2 for injection fluid 212 to reach the patient:
It should be noted that some of the fluid reaches the patient earlier and that the response time for flow control valve 115 is important to limit patient exposure to inappropriate fluid administration. Positioning of flow control valve 115 near the patient is thus important. Additionally, early detection of an inappropriate fluid is also important to protect the patient. Operation of identification sensor 145 to detect fluid source 210 at the time of attachment to fluid inlet 105, before manual administration fluid flow, is preferred. Alternatively, composition sensor 148 can identify fluid 212 and/or flow sensor 149 can measure fluid volume 212 providing data for the flow controller.
Additionally, fluid volume V2+V3 downstream from the injection port can be measured by fluid withdrawal into a syringe 210 (pulling on an empty syringe connected to the injection port and withdrawing fluid into the syringe) with the upstream fluid pathway 202 occluded (pinched off). The withdrawn downstream fluid volume V2+V3 can be measured manually by inspection of the syringe graduations or measured automatically by a fluid volume measurement sensor 149 within the injection port apparatus (if so enabled to detect reversed flow). The measured downstream volume can be communicated to and stored in the rules engine. The downstream volume can then be used as an input to the flow controller.
In yet another variation, flow control valve 115 can be distributed between a disposable subsection and a reusable subsection. The interface between these subsections can be electrical, magnetic, mechanical, hydraulic, optical, and/or capacitive. The disposable subsection can include the flow control valve 115 and fluid flow pathway 120 only and the reusable subsection can include all the other operational components. In this configuration the valve actuator is in the reusable subsection coupled to the disposable subsection valve 115 mechanism with fluid flow pathway 120. Alternatively, the disposable subsection can include all the components including the flow control valve 115, power supply, wireless or wired communications, and fluid path.
It should be appreciated that the systems described herein can, but need not transmit data to an external system 135 for recording and logging data. For example, the system 100 can incorporate the intelligent flow control features of the programmable flow control valve 115 and provide user feedback (such as alarms and other alert messages to user interface 160) without transmitting, and/or recording the data to an external system 135.
The system 100 can be programmed with information downloaded into the system memory 150 prior to use, in real-time, using on-demand connectivity with the external systems 135 or a combination of the two. In some implementations, the system 100 can be pre-programmed according to a subset of static flow control data 140 (e.g. patient blood type, known drug allergies, dose limits, etc.) prior to or upon connection to a patient's fluid line. The system 100 can be programmed using a dockable cradle, wireless communications interface or a wired connector. In some implementations, a low-cost, non-wireless version of the system 100 can be pre-programmed with only non-patient-specific rules such as drug-drug interactions, hard dosing limits, etc. for generic use with any patient. The system 100 can be provided to a buyer including the pre-programmed with non-patient-specific information or according to published clinical guidelines and standards. The non-patient-specific information can be programmed prior to clinical use by a manufacturer, care provider or by a hospital pharmacist, or other care setting based on provider-specific rules and operating procedures.
In some implementations, the system 100 can be programmed and/or communicate information in real-time to the one or more external systems 135 using a wireless transmission 157. A variety of wireless transmission hardware and protocols can be used such as RF, IrDA (infrared), Bluetooth, Zigbee, Continue, Wireless USB, Wibree, IEEE 802 relevant standards (e.g., 802.11, 802.15, or 802.16, etc.), Direct Sequence Spread Spectrum; Frequency Hopping Spread Spectrum; cellular/wireless/cordless telecommunication protocols, wireless home network communication protocols, paging network protocols, magnetic induction, satellite data communication protocols, wireless hospital or health care facility network protocols, and other methods. The data transmissions can, in some implementations, be encrypted in order to ensure patient privacy and/or to comply with various laws relating to handling of medical data. The transmitter can have such encryption capabilities or one or more additional chipsets can be incorporated within a region of the system 100 to provide such encryption.
In some implementations, the configurable rules engine 130 can run on a microprocessor 125 remote to the system 100. The flow state commands 122 or 280 can be sent to the system 100 in a wireless or wired manner to the flow control valve 115 instructing the flow control valve 115 to open or close.
The system 100 described herein can include one or more mechanisms configured for receiving input from a user via user interface 160 to control operation of the system 100 and/or providing feedback to a user from the system 100. For example, the user interface 160 can incorporate one or more user inputs such as one or more keys, buttons, switches, dials, or touch-screens. The user interface 160 can incorporate one or more user feedback mechanisms such as one or more LEDs, graphical displays, sounds, speech synthesis technology or vibration mechanisms. The visual, tactile or auditory feedback can include a sequence of notifications such as volume, color, number, intensity, or other feature of the particular feedback mechanism is varied to indicate a particular state of the system 100. Information provided by a user via user interface 160 can be used by the flow controller in determining an appropriate flow state command 122 to flow control valve 115. In some implementations, one or more of the user inputs and/or feedback mechanisms of user interface 160 can be remote to the system 100, such as on a computing device in communication with the system 100 such as by a wired or wireless connection using the transmitter/receiver 157.
The power source 155 can include a self-contained power source such as a battery, single-use or rechargeable battery, battery array or other type of power source known in the art. Where the battery is rechargeable, there can be a connector or other interface for attaching the device to an electrical outlet, docking station, portable recharger, or so forth to recharge the battery.
In some implementations, the system 100 can include an internal fluid composition sensor 148 that can be configured to allow the fluid composition and concentration of the fluid source to be empirically determined. The sensor 148 can be positioned downstream of the fluid inlet 105 and upstream of flow control valve 115. The internal fluid composition sensor 148 can be the sole source of fluid type detection. In some implementations, the composition sensor 148 can be a supplement to fluid source information carried by the fluid source container and detected by a fluid source reader 145.
The system 100 can accommodate a variety of volumes and doses, including fractional doses, or multiple fluid source connections to fulfill the desired treatment protocol of a single patient medical order. For example, a physician can order a 2 mg dose of morphine for a patient. The nurse can connect one 4 mg syringe of morphine, intending to deliver half the syringe to the patient and discard the other half. In this example, the system 100 can alert the clinician that a 4 mg syringe is connected to the system 100 and the potential dose to be delivered to the patient is too high. The system 100 can also prevent overdose by sending a flow state command 122 or 280 to close the flow control valve 115 after the first 2 mg of morphine have been delivered to the patient to prevent delivery of remaining 2 mg of morphine. Alternatively, a physician can order 2 mg of morphine for a patient. The care provider can fulfill the order by first connecting a 1 mg syringe of morphine to the system 100 and delivering the full contents of the syringe to the patient and then connecting a second 1 mg syringe of morphine to the system 100 and delivering the full contents of the second syringe to the patient. In either scenario, the physician order for 2 mg have been fulfilled and the system 100 would not provide an alert or constrain fluid flow unless a further morphine syringe is coupled to the system 100.
In some cases, different flow restriction mechanisms can be used other than a flow control valve. In such cases an operation modification signal can be generated (based on attributes detected by the sensor(s) as applied to various rules) which causes one or more devices to change an operational parameter which directly or indirectly affects fluid flow within the fluid pathway(s) (at various points along the fluid pathway(s)). In other variations, a fluid port can generate an operation modification signal (based on attributes detected by the sensor(s) as applied to various rules) which causes other operational parameters of an external device to change. Such operational parameters need not necessarily affect fluid flow through the fluid pathway(s).
Similarly, the systems described herein can use any sort of manually administered fluid source and are not limited to a specific IV fluid source type and can include syringes, IV bags, disposable medication cartridges or pouches, IV tubing, etc.
It should be appreciated that the systems described herein can be used for delivery of fluids by a variety of routes of administrations. Unless otherwise specified the terms injection, administration, or delivery as they relate to introducing a fluid to a patient is not intended to be limiting to a particular route of manual administration (i.e., administration effected by a human being as opposed to a pump).
Various aspects of the subject matter described herein may be realized in digital electronic circuitry, integrated circuitry, specially designed ASICs (application specific integrated circuits), computer hardware, firmware, software, and/or combinations thereof. These various implementations may include implementation in one or more computer programs that are executable and/or interpretable on a programmable system including at least one programmable processor, which may be special or general purpose, coupled to receive data and instructions from, and to transmit data and instructions to, a storage system, at least one input device (e.g., mouse, touch screen, etc.), and at least one output device.
These computer programs, which can also be referred to programs, software, software applications, applications, components, or code, include machine instructions for a programmable processor, and can be implemented in a high-level procedural and/or object-oriented programming language, and/or in assembly/machine language. As used herein, the term “machine-readable medium” refers to any computer program product, apparatus and/or device, such as for example magnetic discs, optical disks, memory, and Programmable Logic Devices (PLDs), used to provide machine instructions and/or data to a programmable processor, including a machine-readable medium that receives machine instructions as a machine-readable signal. The term “machine-readable signal” refers to any signal used to provide machine instructions and/or data to a programmable processor. The machine-readable medium can store such machine instructions non-transitorily, such as for example as would a non-transient solid state memory or a magnetic hard drive or any equivalent storage medium. The machine-readable medium can alternatively or additionally store such machine instructions in a transient manner, such as for example as would a processor cache or other random access memory associated with one or more physical processor cores.
These computer programs, which can also be referred to programs, software, software applications, applications, components, or code, include machine instructions for a programmable processor, and can be implemented in a high-level procedural language, an object-oriented programming language, a functional programming language, a logical programming language, and/or in assembly/machine language. As used herein, the term “machine-readable medium” refers to any computer program product, apparatus and/or device, such as for example magnetic discs, optical disks, memory, and Programmable Logic Devices (PLDs), used to provide machine instructions and/or data to a programmable processor, including a machine-readable medium that receives machine instructions as a machine-readable signal. The term “machine-readable signal” refers to any signal used to provide machine instructions and/or data to a programmable processor. The machine-readable medium can store such machine instructions non-transitorily, such as for example as would a non-transient solid state memory or a magnetic hard drive or any equivalent storage medium. The machine-readable medium can alternatively or additionally store such machine instructions in a transient manner, such as for example as would a processor cache or other random access memory associated with one or more physical processor cores.
To provide for interaction with a user, the subject matter described herein can be implemented on a computer having a display device, such as for example a cathode ray tube (CRT) or a liquid crystal display (LCD) monitor for displaying information to the user and a keyboard and a pointing device, such as for example a mouse or a trackball, by which the user may provide input to the computer. Other kinds of devices can be used to provide for interaction with a user as well. For example, feedback provided to the user can be any form of sensory feedback, such as for example visual feedback, auditory feedback, or tactile feedback; and input from the user may be received in any form, including, but not limited to, acoustic, speech, or tactile input. Other possible input devices include, but are not limited to, touch screens or other touch-sensitive devices such as single or multi-point resistive or capacitive trackpads, voice recognition hardware and software, optical scanners, optical pointers, digital image capture devices and associated interpretation software, and the like.
The subject matter described herein may be implemented in a computing system that includes a back-end component (e.g., as a data server), or that includes a middleware component (e.g., an application server), or that includes a front-end component (e.g., a client computer having a graphical user interface or a Web browser through which a user may interact with an implementation of the subject matter described herein), or any combination of such back-end, middleware, or front-end components. The components of the system may be interconnected by any form or medium of digital data communication (e.g., a communications network). Examples of communications networks include a local area network (“LAN”), a wide area network (“WAN”), and the Internet.
The computing system may include clients and servers. A client and server are generally remote from each other and typically interact through a communications network. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.
The implementations set forth in the foregoing description do not represent all implementations consistent with the subject matter described herein. Instead, they are merely some examples consistent with aspects related to the described subject matter. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.
Although a few variations have been described in detail above, other modifications or additions are possible. In particular, further features and/or variations can be provided in addition to those set forth herein. For example, the implementations described above can be directed to various combinations and sub-combinations of the disclosed features and/or combinations and sub-combinations of several further features disclosed above. In addition, the logic flows and steps for use described herein do not require the particular order shown, or sequential order, to achieve desirable results. Other embodiments can be within the scope of the claim.
This application is a continuation of U.S. patent application Ser. No. 15/652,882 filed on Jul. 18, 2017 (now U.S. Pat. No. 10,532,154), which is a continuation of U.S. patent application Ser. No. 13/689,729 filed on Nov. 29, 2012 (now U.S. Pat. No. 9,744,298), which is a continuation-in-part of U.S. patent application Ser. No. 13/529,876 filed on Jun. 21, 2012 (now U.S. Pat. No. 10,293,107), which claims priority to U.S. Provisional Patent Application No. 61/500,073 filed on Jun. 22, 2011, the disclosures of each of which are hereby fully incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
3430625 | McLeod, Jr. | Mar 1969 | A |
4003252 | Dewalth | Jan 1977 | A |
4415802 | Long | Nov 1983 | A |
4650475 | Smith et al. | Mar 1987 | A |
4657490 | Abbott | Apr 1987 | A |
4684367 | Schaffer et al. | Aug 1987 | A |
4759527 | Brown et al. | Jul 1988 | A |
4853521 | Claeys et al. | Aug 1989 | A |
4857713 | Brown | Aug 1989 | A |
4921277 | McDonough | Aug 1990 | A |
4978335 | Arthur, III | Dec 1990 | A |
5011032 | Rollman | Apr 1991 | A |
5040422 | Frankenberger et al. | Aug 1991 | A |
5078683 | Sancoff et al. | Jan 1992 | A |
5179862 | Lynnworth | Jan 1993 | A |
5247826 | Frola et al. | Sep 1993 | A |
5279576 | Loo et al. | Jan 1994 | A |
5317506 | Coutre et al. | May 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5383858 | Reilly et al. | Jan 1995 | A |
5429602 | Hauser | Jul 1995 | A |
5463906 | Spani et al. | Nov 1995 | A |
5531697 | Olsen et al. | Jul 1996 | A |
5531698 | Olsen | Jul 1996 | A |
5569212 | Brown | Oct 1996 | A |
5611784 | Barresi et al. | Mar 1997 | A |
5612524 | Sant'Anselmo et al. | Mar 1997 | A |
5628309 | Brown | May 1997 | A |
5651775 | Walker et al. | Jul 1997 | A |
5692640 | Caulfield et al. | Dec 1997 | A |
5713856 | Eggers et al. | Feb 1998 | A |
5720733 | Brown | Feb 1998 | A |
5740428 | Mortimore et al. | Apr 1998 | A |
5781442 | Engleson et al. | Jul 1998 | A |
5782814 | Brown et al. | Jul 1998 | A |
5792117 | Brown | Aug 1998 | A |
5833213 | Ryan | Nov 1998 | A |
5845264 | Nellhaus | Dec 1998 | A |
5873731 | Prendergast | Feb 1999 | A |
5920263 | Huttenhoff et al. | Jul 1999 | A |
5925014 | Teeple Jr. | Jul 1999 | A |
5941846 | Duffy et al. | Aug 1999 | A |
5984901 | Sudo et al. | Nov 1999 | A |
6019745 | Gray | Feb 2000 | A |
6039251 | Holowko et al. | Mar 2000 | A |
6106498 | Friedli et al. | Aug 2000 | A |
6123686 | Olsen et al. | Sep 2000 | A |
6192945 | Ford et al. | Feb 2001 | B1 |
D438634 | Merry | Mar 2001 | S |
6249299 | Tainer | Jun 2001 | B1 |
6256037 | Callahan | Jul 2001 | B1 |
6270455 | Brown | Aug 2001 | B1 |
6277099 | Strowe et al. | Aug 2001 | B1 |
6338200 | Baxa et al. | Jan 2002 | B1 |
6341174 | Callahan et al. | Jan 2002 | B1 |
6342889 | Callahan | Jan 2002 | B1 |
6381029 | Tipirneni | Apr 2002 | B1 |
6422094 | Ganshorn | Jul 2002 | B1 |
6464667 | Kamen et al. | Oct 2002 | B1 |
6468424 | Donig et al. | Oct 2002 | B1 |
6471089 | Liff et al. | Oct 2002 | B2 |
6482185 | Hartmann | Nov 2002 | B1 |
6497680 | Holst | Dec 2002 | B1 |
6519569 | White et al. | Feb 2003 | B1 |
6579231 | Phipps | Jun 2003 | B1 |
RE38189 | Walker et al. | Jul 2003 | E |
6626355 | Sasse et al. | Sep 2003 | B2 |
6626862 | Duchon et al. | Sep 2003 | B1 |
D481121 | Evans | Oct 2003 | S |
6641562 | Peterson | Nov 2003 | B1 |
6644130 | Imai et al. | Nov 2003 | B2 |
6671563 | Engelson et al. | Dec 2003 | B1 |
D485356 | Evans | Jan 2004 | S |
6675660 | Mosier et al. | Jan 2004 | B1 |
6685227 | Merry et al. | Feb 2004 | B2 |
6685678 | Evans et al. | Feb 2004 | B2 |
6697067 | Callahan et al. | Feb 2004 | B1 |
6731989 | Engleson et al. | May 2004 | B2 |
6733495 | Bek et al. | May 2004 | B1 |
6742992 | Davis | Jun 2004 | B2 |
6790198 | White et al. | Sep 2004 | B1 |
6798533 | Tipirneni | Sep 2004 | B2 |
6825864 | Botten et al. | Nov 2004 | B2 |
6851615 | Jones | Feb 2005 | B2 |
6854338 | Khuri-Yakub et al. | Feb 2005 | B2 |
6915170 | Engleson et al. | Jul 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6985870 | Martucci et al. | Jan 2006 | B2 |
6993402 | Klass et al. | Jan 2006 | B2 |
7000485 | Ao et al. | Feb 2006 | B2 |
7017623 | Tribble et al. | Mar 2006 | B2 |
7061831 | De La Huerga | Jun 2006 | B2 |
7074205 | Duffy et al. | Jul 2006 | B1 |
7074209 | Evans et al. | Jul 2006 | B2 |
7096072 | Engleson et al. | Aug 2006 | B2 |
7103419 | Engleson et al. | Sep 2006 | B2 |
7106479 | Roy et al. | Sep 2006 | B2 |
7107106 | Engleson et al. | Sep 2006 | B2 |
7115113 | Evans et al. | Oct 2006 | B2 |
7116343 | Botten et al. | Oct 2006 | B2 |
7117041 | Engleson et al. | Oct 2006 | B2 |
7161488 | Frasch | Jan 2007 | B2 |
7171277 | Engleson et al. | Jan 2007 | B2 |
7175081 | Andreasson et al. | Feb 2007 | B2 |
7180624 | Tipirneni | Feb 2007 | B2 |
7182256 | Andreasson et al. | Feb 2007 | B2 |
7225683 | Harnett et al. | Jun 2007 | B2 |
7236936 | White et al. | Jun 2007 | B2 |
7237199 | Menhardt et al. | Jun 2007 | B1 |
7264323 | Tainer et al. | Sep 2007 | B2 |
7299981 | Hickle et al. | Nov 2007 | B2 |
7319540 | Tipirneni | Jan 2008 | B2 |
7347841 | Elhadad et al. | Mar 2008 | B2 |
7358505 | Woodworth et al. | Apr 2008 | B2 |
7360448 | Maginnis et al. | Apr 2008 | B2 |
7364067 | Steusloff et al. | Apr 2008 | B2 |
7370797 | Sullivan et al. | May 2008 | B1 |
7375737 | Botten et al. | May 2008 | B2 |
7384410 | Eggers et al. | Jun 2008 | B2 |
7442181 | Schubert et al. | Oct 2008 | B2 |
7469598 | Shkarlet et al. | Dec 2008 | B2 |
7469599 | Froehlich et al. | Dec 2008 | B2 |
7470266 | Massengale et al. | Dec 2008 | B2 |
7483756 | Engleson et al. | Jan 2009 | B2 |
D588200 | Langan et al. | Mar 2009 | S |
7534239 | Schneider et al. | May 2009 | B1 |
D593613 | Langan et al. | Jun 2009 | S |
D595361 | Langan et al. | Jun 2009 | S |
7559483 | Hickle et al. | Jul 2009 | B2 |
7564579 | Tipirneni | Jul 2009 | B2 |
D597608 | Langan et al. | Aug 2009 | S |
D602534 | Langan et al. | Oct 2009 | S |
7614545 | Christofferson et al. | Nov 2009 | B2 |
7617739 | Dam | Nov 2009 | B1 |
D605228 | Langan et al. | Dec 2009 | S |
D605229 | Langan et al. | Dec 2009 | S |
D605230 | Langan et al. | Dec 2009 | S |
7645258 | White et al. | Jan 2010 | B2 |
7673527 | Ehring et al. | Mar 2010 | B2 |
7694565 | Koerdt et al. | Apr 2010 | B2 |
7703336 | Genosar | Apr 2010 | B2 |
7704231 | Pongpairochana et al. | Apr 2010 | B2 |
7722083 | McCarthy et al. | May 2010 | B2 |
7727196 | Neer | Jun 2010 | B2 |
7753880 | Malackowski | Jul 2010 | B2 |
7753891 | Tennican et al. | Jul 2010 | B2 |
7756724 | Gropper et al. | Jul 2010 | B2 |
7763006 | Tennican | Jul 2010 | B2 |
D621879 | Langan et al. | Aug 2010 | S |
D621880 | Langan et al. | Aug 2010 | S |
7771385 | Eggers et al. | Aug 2010 | B2 |
D624595 | Langan et al. | Sep 2010 | S |
D624596 | Langan et al. | Sep 2010 | S |
7799010 | Tennican | Sep 2010 | B2 |
7813939 | Clements et al. | Oct 2010 | B2 |
7815123 | Conner et al. | Oct 2010 | B2 |
7815605 | Souter | Oct 2010 | B2 |
7819838 | Ziegler et al. | Oct 2010 | B2 |
7822096 | Kuksenkov | Oct 2010 | B2 |
7834816 | Marino et al. | Nov 2010 | B2 |
7859473 | Gibson | Dec 2010 | B2 |
D633151 | Langan et al. | Feb 2011 | S |
7887513 | Nemoto et al. | Feb 2011 | B2 |
D634367 | Langan et al. | Mar 2011 | S |
D634368 | Langan et al. | Mar 2011 | S |
D634369 | Langan et al. | Mar 2011 | S |
7905861 | Rhinehart et al. | Mar 2011 | B2 |
7918830 | Langan et al. | Apr 2011 | B2 |
7922073 | De La Huerga | Apr 2011 | B2 |
7927313 | Stewart et al. | Apr 2011 | B2 |
7933780 | de la Huerga | Apr 2011 | B2 |
7941949 | Cloninger | May 2011 | B2 |
D639861 | Langan et al. | Jun 2011 | S |
D639862 | Langan et al. | Jun 2011 | S |
D639863 | Langan et al. | Jun 2011 | S |
7967778 | Nemoto et al. | Jun 2011 | B2 |
D641421 | Langan et al. | Jul 2011 | S |
D641422 | Langan et al. | Jul 2011 | S |
7976508 | Hoag | Jul 2011 | B2 |
7981073 | Mollstam et al. | Jul 2011 | B2 |
D643468 | Langan et al. | Aug 2011 | S |
D643469 | Langan et al. | Aug 2011 | S |
D643470 | Langan et al. | Aug 2011 | S |
D643471 | Langan et al. | Aug 2011 | S |
D643472 | Langan et al. | Aug 2011 | S |
7991627 | Hutchinson et al. | Aug 2011 | B2 |
D645094 | Langan et al. | Sep 2011 | S |
8031347 | Edwards et al. | Oct 2011 | B2 |
8035517 | Gibson | Oct 2011 | B2 |
D649196 | Langan et al. | Nov 2011 | S |
8059297 | Tipirneni | Nov 2011 | B2 |
8063925 | Tainer et al. | Nov 2011 | B2 |
8065924 | Ziegler et al. | Nov 2011 | B2 |
8069060 | Tipirneni | Nov 2011 | B2 |
8111159 | Andreasson et al. | Feb 2012 | B2 |
8133178 | Brauker et al. | Mar 2012 | B2 |
8140349 | Hanson et al. | Mar 2012 | B2 |
8151835 | Khan et al. | Apr 2012 | B2 |
8235938 | Eggers et al. | Aug 2012 | B2 |
8240550 | Steusloff et al. | Aug 2012 | B2 |
8303547 | Brown | Nov 2012 | B2 |
8328082 | Bochenko et al. | Dec 2012 | B1 |
8355753 | Bochenko et al. | Jan 2013 | B2 |
8385972 | Bochenko et al. | Feb 2013 | B2 |
8394053 | Bochenko et al. | Mar 2013 | B2 |
8480834 | Rice et al. | Jul 2013 | B2 |
8505809 | Steusloff et al. | Aug 2013 | B2 |
8606596 | Bochenko et al. | Dec 2013 | B1 |
8636202 | Keefe et al. | Jan 2014 | B2 |
8639521 | Eggers et al. | Jan 2014 | B2 |
8639525 | Levine et al. | Jan 2014 | B2 |
8645154 | Eggers et al. | Feb 2014 | B2 |
8702674 | Bochenko | Apr 2014 | B2 |
8728020 | Caleffi et al. | May 2014 | B2 |
8752088 | Harvey et al. | Jun 2014 | B1 |
20010020148 | Sasse et al. | Sep 2001 | A1 |
20010029608 | Hochman | Dec 2001 | A1 |
20010056258 | Evans | Dec 2001 | A1 |
20020040208 | Flaherty et al. | Apr 2002 | A1 |
20020077852 | Ford et al. | Jun 2002 | A1 |
20020088131 | Baxa et al. | Jul 2002 | A1 |
20020098598 | Coffen et al. | Jul 2002 | A1 |
20020099334 | Hanson et al. | Jul 2002 | A1 |
20020169439 | Flaherty | Nov 2002 | A1 |
20020177811 | Reilly et al. | Nov 2002 | A1 |
20020188259 | Hickle et al. | Dec 2002 | A1 |
20030012701 | Sangha et al. | Jan 2003 | A1 |
20030040479 | Demopulos | Feb 2003 | A1 |
20030052787 | Zerhusen et al. | Mar 2003 | A1 |
20030055685 | Cobb et al. | Mar 2003 | A1 |
20030065537 | Evans | Apr 2003 | A1 |
20030088238 | Poulsen et al. | May 2003 | A1 |
20030135388 | Martucci et al. | Jul 2003 | A1 |
20030139701 | White et al. | Jul 2003 | A1 |
20030139706 | Gray | Jul 2003 | A1 |
20030140929 | Wilkes et al. | Jul 2003 | A1 |
20030141981 | Bui et al. | Jul 2003 | A1 |
20030160698 | Andreasson et al. | Aug 2003 | A1 |
20030164401 | Andreasson et al. | Sep 2003 | A1 |
20030174326 | Rzasa et al. | Sep 2003 | A1 |
20040051368 | Caputo et al. | Mar 2004 | A1 |
20040082918 | Evans et al. | Apr 2004 | A1 |
20040092885 | Duchon et al. | May 2004 | A1 |
20040103951 | Osborne et al. | Jun 2004 | A1 |
20040104271 | Martucci et al. | Jun 2004 | A1 |
20040105115 | Edwards et al. | Jun 2004 | A1 |
20040179051 | Tainer et al. | Sep 2004 | A1 |
20040179132 | Fujino et al. | Sep 2004 | A1 |
20040186437 | Frenette et al. | Sep 2004 | A1 |
20040193453 | Butterfield et al. | Sep 2004 | A1 |
20040204673 | Flaherty | Oct 2004 | A1 |
20040212834 | Edwards et al. | Oct 2004 | A1 |
20040238631 | Andreasson et al. | Dec 2004 | A1 |
20050055242 | Bello et al. | Mar 2005 | A1 |
20050059926 | Sage, Jr. et al. | Mar 2005 | A1 |
20050070978 | Bek et al. | Mar 2005 | A1 |
20050088306 | Andreasson et al. | Apr 2005 | A1 |
20050101905 | Merry | May 2005 | A1 |
20050106225 | Massengale et al. | May 2005 | A1 |
20050107923 | Vanderveen | May 2005 | A1 |
20050118048 | Traxinger | Jun 2005 | A1 |
20050151652 | Frasch | Jul 2005 | A1 |
20050151823 | Botten et al. | Jul 2005 | A1 |
20050154368 | Lim et al. | Jul 2005 | A1 |
20050165559 | Nelson | Jul 2005 | A1 |
20050182358 | Veit et al. | Aug 2005 | A1 |
20050277873 | Stewart et al. | Dec 2005 | A1 |
20050277890 | Stewart et al. | Dec 2005 | A1 |
20060032918 | Andreasson et al. | Feb 2006 | A1 |
20060065713 | Kingery | Mar 2006 | A1 |
20060079767 | Gibbs et al. | Apr 2006 | A1 |
20060079843 | Brooks | Apr 2006 | A1 |
20060102503 | Elhadad et al. | May 2006 | A1 |
20060116639 | Russell | Jun 2006 | A1 |
20060122577 | Poulsen et al. | Jun 2006 | A1 |
20060143051 | Eggers et al. | Jun 2006 | A1 |
20060144942 | Evans et al. | Jul 2006 | A1 |
20060178617 | Adams et al. | Aug 2006 | A1 |
20060190302 | Eggers et al. | Aug 2006 | A1 |
20060206356 | Vanderveen | Sep 2006 | A1 |
20060224125 | Simpson et al. | Oct 2006 | A1 |
20060226089 | Robinson et al. | Oct 2006 | A1 |
20060229551 | Martinez et al. | Oct 2006 | A1 |
20060253346 | Gomez | Nov 2006 | A1 |
20060258985 | Thibadeau | Nov 2006 | A1 |
20060265186 | Holland et al. | Nov 2006 | A1 |
20060270997 | Lim et al. | Nov 2006 | A1 |
20060287887 | Hutchinson | Dec 2006 | A1 |
20070008399 | Botten et al. | Jan 2007 | A1 |
20070043335 | Olsen et al. | Feb 2007 | A1 |
20070060874 | Nesbitt et al. | Mar 2007 | A1 |
20070100316 | Traxinger | May 2007 | A1 |
20070134044 | Colbrunn et al. | Jun 2007 | A1 |
20070135765 | Miller et al. | Jun 2007 | A1 |
20070136218 | Bauer et al. | Jun 2007 | A1 |
20070166198 | Sangha et al. | Jul 2007 | A1 |
20070167919 | Nemoto et al. | Jul 2007 | A1 |
20070179448 | Lim et al. | Aug 2007 | A1 |
20070186923 | Poutiatine et al. | Aug 2007 | A1 |
20070187475 | MacLeod | Aug 2007 | A1 |
20070191787 | Lim et al. | Aug 2007 | A1 |
20070255199 | Dewey | Nov 2007 | A1 |
20070279625 | Rzasa et al. | Dec 2007 | A1 |
20070280710 | Tainer et al. | Dec 2007 | A1 |
20070293830 | Martin | Dec 2007 | A1 |
20070299421 | Gibson | Dec 2007 | A1 |
20080038128 | Haar | Feb 2008 | A1 |
20080045930 | Makin et al. | Feb 2008 | A1 |
20080051937 | Khan et al. | Feb 2008 | A1 |
20080061153 | Hickle et al. | Mar 2008 | A1 |
20080065016 | Peterson et al. | Mar 2008 | A1 |
20080071219 | Rhinehart et al. | Mar 2008 | A1 |
20080118141 | Sommer et al. | May 2008 | A1 |
20080125724 | Monroe | May 2008 | A1 |
20080191013 | Liberatore | Aug 2008 | A1 |
20080208042 | Ortenzi et al. | Aug 2008 | A1 |
20080234630 | Iddan et al. | Sep 2008 | A1 |
20080243054 | Mollstam et al. | Oct 2008 | A1 |
20080243088 | Evans | Oct 2008 | A1 |
20080255523 | Grinberg | Oct 2008 | A1 |
20080294108 | Briones et al. | Nov 2008 | A1 |
20080306439 | Nelson et al. | Dec 2008 | A1 |
20090018494 | Nemoto et al. | Jan 2009 | A1 |
20090030730 | Dullemen et al. | Jan 2009 | A1 |
20090036846 | Dacquay et al. | Feb 2009 | A1 |
20090043253 | Podaima | Feb 2009 | A1 |
20090069714 | Eichmann et al. | Mar 2009 | A1 |
20090069743 | Krishnamoorthy | Mar 2009 | A1 |
20090085768 | Patel et al. | Apr 2009 | A1 |
20090093774 | Wang et al. | Apr 2009 | A1 |
20090112178 | Behzadi | Apr 2009 | A1 |
20090112333 | Sahai | Apr 2009 | A1 |
20090113996 | Wang et al. | May 2009 | A1 |
20090126483 | Blendinger et al. | May 2009 | A1 |
20090126866 | Stenner et al. | May 2009 | A1 |
20090137956 | Souter | May 2009 | A1 |
20090143673 | Drost et al. | Jun 2009 | A1 |
20090149744 | Nemoto et al. | Jun 2009 | A1 |
20090156931 | Nemoto et al. | Jun 2009 | A1 |
20090157008 | Vitral | Jun 2009 | A1 |
20090159654 | Grimard | Jun 2009 | A1 |
20090200185 | Follman et al. | Aug 2009 | A1 |
20090209911 | Cabus et al. | Aug 2009 | A1 |
20090259176 | Yairi | Oct 2009 | A1 |
20090288497 | Ziegler | Nov 2009 | A1 |
20090294521 | de la Huerga | Dec 2009 | A1 |
20090296540 | Gilbert et al. | Dec 2009 | A1 |
20090306620 | Thilly et al. | Dec 2009 | A1 |
20100022953 | Bochenko et al. | Jan 2010 | A1 |
20100022987 | Bochenko et al. | Jan 2010 | A1 |
20100036310 | Hillman | Feb 2010 | A1 |
20100036313 | Shener et al. | Feb 2010 | A1 |
20100065633 | Nelson et al. | Mar 2010 | A1 |
20100065643 | Leyvraz et al. | Mar 2010 | A1 |
20100076310 | Wenderow et al. | Mar 2010 | A1 |
20100095782 | Ferencz et al. | Apr 2010 | A1 |
20100114951 | Bauman et al. | May 2010 | A1 |
20100145165 | Merry | Jun 2010 | A1 |
20100152562 | Goodnow et al. | Jun 2010 | A1 |
20100153136 | Whittacre et al. | Jun 2010 | A1 |
20100174266 | Estes | Jul 2010 | A1 |
20100179417 | Russo | Jul 2010 | A1 |
20100185182 | Alme et al. | Jul 2010 | A1 |
20100204659 | Bochenko et al. | Aug 2010 | A1 |
20100262002 | Martz | Oct 2010 | A1 |
20100280486 | Khair et al. | Nov 2010 | A1 |
20100286599 | Ziegler et al. | Nov 2010 | A1 |
20100305499 | Matsiev et al. | Dec 2010 | A1 |
20110009800 | Dam et al. | Jan 2011 | A1 |
20110009817 | Bennett et al. | Jan 2011 | A1 |
20110028937 | Powers et al. | Feb 2011 | A1 |
20110060198 | Bennett et al. | Mar 2011 | A1 |
20110093279 | Levine et al. | Apr 2011 | A1 |
20110111794 | Bochenko et al. | May 2011 | A1 |
20110112473 | Bochenko et al. | May 2011 | A1 |
20110112474 | Bochenko et al. | May 2011 | A1 |
20110137288 | Tallarida et al. | Jun 2011 | A1 |
20110152824 | DiPerna et al. | Jun 2011 | A1 |
20110152825 | Marggi | Jun 2011 | A1 |
20110152834 | Langan et al. | Jun 2011 | A1 |
20110160655 | Hanson et al. | Jun 2011 | A1 |
20110161112 | Keefe et al. | Jun 2011 | A1 |
20110166511 | Sharvit et al. | Jul 2011 | A1 |
20110176490 | Mehta et al. | Jul 2011 | A1 |
20110185821 | Genosar | Aug 2011 | A1 |
20110220713 | Cloninger | Sep 2011 | A1 |
20110224649 | Duane et al. | Sep 2011 | A1 |
20110251584 | Khot | Oct 2011 | A1 |
20110259954 | Bartz et al. | Oct 2011 | A1 |
20110264069 | Bochenko | Oct 2011 | A1 |
20110295191 | Injev | Dec 2011 | A1 |
20110313349 | Krulevitch et al. | Dec 2011 | A1 |
20110315611 | Fulkerson et al. | Dec 2011 | A1 |
20120004542 | Nemoto et al. | Jan 2012 | A1 |
20120004602 | Hanson et al. | Jan 2012 | A1 |
20120004637 | Krulevitch et al. | Jan 2012 | A1 |
20120006127 | Nielsen | Jan 2012 | A1 |
20120022458 | Oh et al. | Jan 2012 | A1 |
20120035535 | Johnson et al. | Feb 2012 | A1 |
20120037266 | Bochenko | Feb 2012 | A1 |
20120041355 | Edman et al. | Feb 2012 | A1 |
20120045295 | Sato | Feb 2012 | A1 |
20120065617 | Matsiev et al. | Mar 2012 | A1 |
20120073673 | Kameyama | Mar 2012 | A1 |
20120222468 | Nelson et al. | Sep 2012 | A1 |
20120226446 | Nelson et al. | Sep 2012 | A1 |
20120226447 | Neison et al. | Sep 2012 | A1 |
20120287431 | Matsiev et al. | Nov 2012 | A1 |
20120323208 | Bochenko et al. | Dec 2012 | A1 |
20120325330 | Prince et al. | Dec 2012 | A1 |
20130018356 | Prince et al. | Jan 2013 | A1 |
20130105568 | Jablonski et al. | May 2013 | A1 |
20130135388 | Samoto et al. | May 2013 | A1 |
20130181046 | Fedorko et al. | Jul 2013 | A1 |
20130204227 | Bochenko et al. | Aug 2013 | A1 |
20130225945 | Prince et al. | Aug 2013 | A1 |
20130226137 | Brown | Aug 2013 | A1 |
20130327822 | Keefe et al. | Dec 2013 | A1 |
20140039383 | Dobbles et al. | Feb 2014 | A1 |
20140060729 | Srnka et al. | Mar 2014 | A1 |
20140142975 | Keefe et al. | May 2014 | A1 |
20150204705 | Forster et al. | Jul 2015 | A1 |
20150211904 | Forster | Jul 2015 | A1 |
Number | Date | Country |
---|---|---|
101732778 | Jun 2010 | CN |
101848741 | Sep 2010 | CN |
102791310 | Nov 2012 | CN |
4137837 | Oct 1992 | DE |
29617777 | Dec 1996 | DE |
1944709 | Jul 2008 | EP |
1980974 | Oct 2008 | EP |
2135630 | Dec 2009 | EP |
2183046 | May 1987 | GB |
2504288 | Jan 2014 | GB |
2504295 | Jan 2014 | GB |
2504297 | Jan 2014 | GB |
5317421 | Dec 1993 | JP |
2008517646 | May 2008 | JP |
201266004 | Apr 2012 | JP |
1020090025392 | Mar 2009 | KR |
03063932 | Aug 2003 | WO |
2009114115 | Sep 2009 | WO |
2010144482 | Dec 2010 | WO |
2011126485 | Oct 2011 | WO |
2012034084 | Mar 2012 | WO |
2012126744 | Sep 2012 | WO |
2013096713 | Jun 2013 | WO |
2014016311 | Jan 2014 | WO |
2014016315 | Jan 2014 | WO |
2014016316 | Jan 2014 | WO |
Number | Date | Country | |
---|---|---|---|
20200093987 A1 | Mar 2020 | US |
Number | Date | Country | |
---|---|---|---|
61500073 | Jun 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15652882 | Jul 2017 | US |
Child | 16695992 | US | |
Parent | 13689729 | Nov 2012 | US |
Child | 15652882 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13529876 | Jun 2012 | US |
Child | 13689729 | US |